Lung Cancer | Specialty

Dr. Spigel on FDA Approval of Pembrolizumab/Chemo Combo in NSCLC

May 11th 2017

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of pembrolizumab plus chemotherapy as a frontline treatment for patients with non–small cell lung cancer (NSCLC).

FDA Approves Frontline Pembrolizumab Combo for NSCLC

May 11th 2017

The FDA has granted an accelerated approval to pembrolizumab for use in combination with pemetrexed plus carboplatin as a frontline treatment for patients with metastatic or advanced nonsquamous non–small cell lung cancer, regardless of PD-L1 expression.

Expert Highlights Next Steps With Immunotherapy in NSCLC

May 6th 2017

Daniel Morgensztern, MD, discusses both the single-agent and combination immunotherapy data in non-small cell lung cancer and what researchers are poised to do next in the field.

Researchers Investigating TCR Therapy in NSCLC

May 6th 2017

Jeffrey P. Ward, MD, PhD, discusses the questions researchers still face about targeting the immune system and exactly what role T-cell receptor therapy could play in the treatment of patients with non-small cell lung cancer.

Biomarker Advances Continue to Drive Progress in NSCLC

May 3rd 2017

Siddhartha Devarakonda, MD, discusses the importance of testing for molecular markers in NSCLC, rare mutations, and what work lies ahead for the field of lung cancer.

Osimertinib Shakes Up EGFR-Mutant NSCLC Landscape

May 2nd 2017

Jonathan Riess, MD, shares his insight on the game-changing efficacy of osimertinib in non-small cell lung cancer and its potential in combination, considering factors for choosing an EGFR TKI, and the burgeoning questions clinicians still have with the EGFR-mutant population.

Dr. West on FDA Approval of Brigatinib in ALK+ NSCLC

May 2nd 2017

H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the FDA approval of brigatinib (Alunbrig) as a treatment for patients with metastatic ALK-positive non–small cell lung cancer (NSCLC) who are resistant to prior crizotinib (Xalkori).

Dr. Gubens on Prevalence of EGFR/ALK/ROS1 and PD-L1 Expression in NSCLC

May 1st 2017

Matthew Gubens, MD, an assistant professor of thoracic oncology at the University of California San Francisco, discusses the prevalence of patients with non–small cell lung cancer (NSCLC) who harbor mutations in EGFR/ALK/ROS1 as well as PD-L1 expression.

Chemotherapy Remains Backbone in Non-Driver Lung Adenocarcinoma

April 29th 2017

Mary Jo Fidler, MD, discusses aiming to improve platinum-based doublet therapy in NSCLC, as well as the role of chemotherapy for non-driver adenocarcinoma in the future.

Dr. Bunn on FDA Approval of Brigatinib for Patients With ALK+ NSCLC

April 29th 2017

Paul A. Bunn Jr, MD, Distinguished Professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer. discusses the FDA approval of brigatinib for the treatment of patients with ALK-positive non–small cell lung cancer (NSCLC).

FDA Approves Brigatinib for ALK-Positive NSCLC

April 28th 2017

The FDA has granted brigatinib (Alunbrig) an accelerated approval as a treatment for patients with metastatic ALK-positive non–small cell lung cancer who are resistant to prior crizotinib.

FDA Grants Lorlatinib Breakthrough Designation for NSCLC

April 27th 2017

The FDA has granted a breakthrough therapy designation to lorlatinib for use in patients with ALK-positive metastatic NSCLC who have previously received 1 or more ALK inhibitors, according to Pfizer, the company developing the next-generation ALK/ROS1 TKI.

Future Research Efforts for ALK-Driven Lung Cancer

April 27th 2017

Next Generation ALK Inhibitors for NSCLC

April 27th 2017

Treatment of ALK-Driven Refractory NSCLC

April 27th 2017

Sequencing Therapies in ALK+ NSCLC

April 27th 2017

Upfront Use of Second-Line Agents in ALK+ NSCLC

April 27th 2017

Treatment of Relapsed/Refractory ALK+ NSCLC

April 27th 2017

Repeat Mutation Testing at ALK-Rearranged NSCLC Progression

April 27th 2017

ALTA II Trial of Brigatinib in ALK-Rearranged NSCLC

April 27th 2017